Background and Objective: A limited number of studies have evaluated the relation-
essential role in the clinical and biochemical manifestations of HA in patients with PCOS. 3, 4 Clinical HA is identified by hirsutism, acne and alopecia. 5 High levels of serum total testosterone (tT), free testosterone (fT), free androgen index (FAI), androstenedione (A4) and dehydroepiandrosterone sulphate (DHEAS) also indicate biochemical HA.
3
There are many pitfalls in the selection of biochemical tests. Although the most frequently measured laboratory parameters are fT and FAI, increased levels of A4 or other androgen precursors are the only findings in many patients. 6, 7 Hirsutism, a common complaint in women with PCOS, refers to abnormal growth of the terminal hair in a male-like pattern. 2, 5 The modified Ferriman-Gallwey (FG) score has now become the gold standard for determining the density of terminal hairs at nine different body sites, (ie upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, arm and thigh); a total score of 8 is considered as hirsutism. 8, 9 Many hirsute women are found to have increased circulating androgen levels, although in some of them, androgen levels are in normal ranges. 3, 9, 10 Some studies show that the severity of hirsutism correlates poorly with the severity of androgen excess; it has not yet been clarified, which of the androgenic parameters have the most significant relationship with FG score. 9, 11 This obvious paradox raises the question of the role of other factors including peripheral metabolism of androgens, sensitivity of target tissues to androgens, key enzymes for biosynthesis and metabolism of androgens and hormonal assay methods in the development of hirsutism.
9
Although androgens modulate the biological mechanism regulating the hair cycle, limited studies have evaluated the relationship between clinical and biochemical HA and these have reported conflicting findings. 3, 5, 6, 9, [12] [13] [14] Confirmed associations between endocrine and clinical characteristics in hirsute patients with PCOS have important implications for follow-up and management of this disorder. 6, 10 Accordingly, we aimed to investigate the association between BHPs and FG score for better understanding the pathophysiology of excess hair in PCOS women; this information will potentially be helpful for selection of treatment options.
| METHODS
We conducted this systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) 15 
| Eligibility criteria
We searched randomized controlled trials (RCTs), noncomparative clinical trials, prospective and retrospective cohort studies, and casecontrol studies restricted to papers published in English between 2000 and 2015. Studies were eligible if they had: (i) a study population, including PCOS women, diagnosed by Rotterdam, National Institutes of Health (NIH) or the Androgen Excess Society (AES) criteria, with or without hirsutism, (ii) assessed FG score and at least one androgen marker, including tT, fT, A4, DHEAS, FAI and SHBG, and (iii) used a modified FG scoring system for diagnosis of hirsutism. We also excluded nonhuman studies, reviews, commentaries, editorials, letters, meeting abstracts, case reports and studies that did not measure FG score or any hormonal markers, or those that had a study population with idiopathic hirsutism or the other types of HA, or did not provide accurate and clear data or methods.
| Search strategy
PubMed, Scopus, Google Scholar, and ScienceDirect and Web of Sciences were searched for studies documented from 2000 to 2015 investigating androgen levels and FG scores in patients with PCOS, using MeSH terms including the following keyword combinations: "Polycystic ovary syndrome" AND "hirsutism" OR "hirsute" OR "androgen" OR "hormone" OR "androstenedione" OR "dehydroepiandrosterone".
| Study selection
Two reviewers, experts in reproductive endocrinology (MA and SB), independently conducted a primary selection using the titles, abstracts and keywords to exclude studies that did not fulfil the inclusion criteria. They independently read the full text of remaining papers to identify eligible articles. Disagreements between reviewers were resolved by discussion or, if necessary, by a third reviewer (FRT). Journals and authors were not blinded during study selection.
| Data extraction
The following data were collected from each study: first author and publication year, country of study, study design and settings, total number of patients, diagnostic criteria for PCOS, patients' characteristics including age and BMI, outcome measurements including FG score, tT, fT, A4, DHEAS and SHBG. Data were extracted from fulltext articles by one reviewer (MA) in close consultation with the second (FRT). Data of all studies were extracted with mean and standard deviation values. 16 To prevent extraction errors, a control check between the final data used in the meta-analysis and the original publications was performed by all authors. Baseline data of all studies such as clinical trials were extracted.
| Quality assessment
All studies included for the meta-analysis were appraised for the quality of their methodological and results presentation. Two reviewers (MA and SB) who were blinded to study author, institution and journal
name assessed the quality of the studies separately. Disagreement was resolved and adjusted by the senior reviewer (FRT).
The modified Consolidated Standards of Reporting Trials (CONSORT) was used as a validated quality assessment checklist for clinical trials. 17 All clinical trial papers were categorized in four groups including high, moderate, low and very low quality; studies with scores ≥70% of the highest level of the CONSORT checklist were considered as high, 40%-70% as moderate, 20%-40% as low and <20% as very low quality.
Moreover, the quality assessment for case control studies was based on the modified Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). 18 The highest level of STROBE score was considered to be 25; if a paper obtained ≥70% of the highest level of STROBE score, it was considered as high quality, 40%-70%
as moderate, 20%-40% as low quality and <20% as very low quality.
In addition, cohort studies were appraised according to the Newcastle-Ottawa scale for observational cohort studies. 19 In this respect, three domains were scored concerning selection and comparability of study cohorts, and outcome of interest was ascertained using a score range of 0 to 9. If a study obtained ≥70% of the highest level of Newcastle-Ottawa scale, it was considered as high quality, 40%-70% as moderate, 20%-40% as moderate and <20% as very low quality.
| Statistical analysis
This meta-analysis was conducted to obtain pooled effect size of FG To assess publication bias, Begg 22 and Egger's tests, 23 and Funnel plot were used. Publication bias was found to be significant for Pvalues<.05, which indicated significant asymmetry in funnel plot, analogously. For significant results or an asymmetric Funnel plot, the trim and fill method was used to identify and correct for publication bias by adding some study measures. 24, 25 Furthermore, we used random effect meta-regression models to assess the observational associations between BHPs and mean FG score across studies. First, the associations between BHPs and FG score were estimated separately without adjusting for confounders.
Then, meta-regression models were fitted to investigate the associations between BHPs and FG score adjusted for age and BMI, diagnostic 
| RESULTS

| Search results and study selection
The selection process and reasons for exclusions are depicted in Figure 3 . Thirty-five studies were included in the meta-analysis, of which 19 had no comparative groups, 13 had two comparative groups, two had three comparative groups and one study had four comparative groups. Of the 35 studies selected, five had cross-sectional design, five case-control, six cohort, seven clinical trial and 12 RCT.
| Quality assessment
Regarding quality, 15 studies were classified as high and 20 as moderate, while none were identified as being of low or very low quality (Table 1) . Therefore, all studies included in the meta-analysis ranged from moderate to high quality.
| Study characteristics
Characteristics of the included studies are reported in Table 1 . Sixteen study groups were performed in the West region, 11 in the Middle East, seven in the East and one in Africa. All studies were published between 2000 and 2015 and assessed a total number of 6593 participants with PCOS. There were no significant associations between other BHPs and FG score after adjusting for this potential confounder.
| Results of meta-regression analysis
The results of meta-regression analysis models are summarized in Table 2 . In addition, Figure 2 shows the association between BHPs and FG score, which fitted meta-regression line for FG score by BHPs using bubble plot. All included studies assessed the FG score; as shown in the forest plot, there was significant heterogeneity in mean FG score among studies (I 2 =99.4%, P<.001) (Figure 1 ). In addition, we observed significant heterogeneity for BHPs including tT (I 
| Results of subgroup analysis
There was no association for FG score with tT, fT, SHBG and FAI in any of the subgroups of hormonal assay methods (chemical/electrochemical luminescence, radioimmunoassay and enzyme). However, subgroup analysis based on the methods of hormonal assay showed that when measurements were taken by radioimmunoassay, associations of FG score with A4 and DHEAS were significant (see detailed results in Data S2).
| Publication bias
We found statistically significant publication bias only for fT; the results of Egger and Begg's tests were not concordant in this case (Table 3) ; therefore, trim and fill correction were applied and showed that nonsignificant publication bias was reliable ( Figure S4 ).
| DISCUSSION
Our review demonstrated significant positive observational associations of FG score with A4 and DHEAS, whereas associations of FG score with tT, fT, SHBG and FAI were not significant. Adjustment
Bubble plots fitted meta-regression line for associations between biochemical hyperandrogenism parameters and FG score. Bubble plots present the following data in order from the top and left to right: association between SHBG and FG score, association between fT and FG score, association between tT and FG score, association between A4 and FG score, association between DHEAS and FG score for potential confounders including diagnostic criteria for PCOS or method for assessment of androgens demonstrated similar results.
Although the pathogenesis of hirsutism is complex and has not been clarified, 9 it is well-known that the intensity and extent of hirsutism is influenced by several factors including the individual reaction of pilosebaceous units to androgens, 6 increased levels of androgens, androgen receptor activity, defects in 5-α reductase production and other key enzymes. 26 In addition, the severity of hirsutism can differ by age, 27 race, ethnicity and familial background. 9, 26 Although the main source of androgen synthesis is the ovary, increased adrenal androgen production has been documented in 25%
of PCOS women, 28 as result of a genetic disorder or secondary to ovarian androgen secretion.
29
The major androgens in the serum of normal women are DHEAS, dehydroepiandrosterone (DHEA), A4, T and dihydrotestosterone (DHT)
30
; T and DHT bind to the androgen receptor to promote changes in gene transcription, whereas DHEA, DHEAS and A4 do not bind to the androgen receptor and are considered to be prohormones. 9 Polymorphisms in the androgen receptor gene also influence the activity of the receptor. T A B L E 1 (Continued)
Therefore, circulating androgen levels may not reflect local androgen concentrations at the pilosebaceous unit. In addition, local androgen effects depend on the expression of the androgen receptor in the pilosebaceous unit.
34
Based on the mechanisms mentioned, hirsutism is considered to be the result of the interaction between circulating androgen levels, local androgen levels and the sensitivity of hair follicles to androgens. Hence, the severity of hirsutism does not exactly correlate with circulating androgen levels. Moreover, the hair follicle response to circulating androgens varies significantly within and between individuals; therefore, some women with elevated androgen levels do not show hirsutism, or they may have seborrhoea, acne or alopecia without clinical hirsutism.
9
In this meta-analysis, we did not observe significant associations of FG scores with tT, fT, FAI and SHBG. Some investigators have reported that FG score is not correlated with serum tT; they also suggest that tT may not be helpful in reflecting biochemical HA. 5, 10 Most physicians consider testosterone and FAI in the diagnosis of biochemical HA, whereas increased levels of DHEAS, A4 or other androgen precursors are the only findings in many patients. 6, 35 Some previous studies have shown that compared to testosterone, pro-hormones have more correlation with hirsutism. Rittmaster et al. (1990) , in a study of PCOS patients, found that the change in hair growth correlated with changes in A4, but not significantly with changes in testosterone. They concluded that hair growth rates correlated more significantly with changes in serum A4 levels. 36 Carmina and Lobo 37 (1993) showed evidence for increased androsterone metabolism in some normoandrogenic women with clinical HA.
As shown in the results, FG score had positive relationships with A4 and DHEAS. A4, a weaker androgen than T, has both ovarian and adrenal origin. Although elevated A4 levels are a frequent finding among women with PCOS, it is not often considered a main diagnostic criterion of biochemical HA. DHEAS, DHEA and A4 are all precursors of testosterone. 38 In severe PCOS phenotypes, circulating A4 levels may be increased, making it a valuable marker to assess biochemical HA 39 ; A4 and DHEAS are of both adrenal and ovarian origin; therefore, the existence any positive associations between FG score and these parameters can represent an adrenal disorder.
Indeed, an adrenal contribution has been reported in about 50% of hyperandrogenaemic women with acne and/or hirsutism; a heterogeneous adrenal androgen hyper-responsiveness to ACTH, which resembles an exaggeration of adrenarche, is the most commonly found abnormality.
40
As hirsutism and/or BHPs are influenced by several factors such as age, BMI, methods of hormonal assay, diagnosis criteria, study design and method of assay, we adjusted for these factors. The prevalence of hirsutism may decline with age, which might be due to the progressive decline in circulating androgens in women with PCOS during their reproductive years. 27 In addition, hormonal profiles, especially DHEAS, may change with age. 7 However, this study showed that after adjusting for age, FG score was only associated with DHEAS.
Obesity, theoretically, can exert an additive or synergistic impact on the clinical and/or biochemical manifestations of PCOS. 5, 41 Balance probably exists between production and clearance of androgens. Obesity is a state of increased androgen production with simultaneous accelerated clearance in hirsute women, which causes a decline in androgen effects. 43 Obesity can increase aromatase enzyme action, which converts T to E2. 44 In our study, after adjusting for BMI, FG score was only associated with DHEAS. However, the relationship of BMI with FG score seems weak and thus remains unclarified.
The prevalence of hirsutism differs with ethnicity, 45 and after adjustment for this, only A4 had a significantly positive association with FG score; a finding confirmed by the fact that in severe PCOS phenotypes, circulating A4 levels may be increased.
39
Current studies in this meta-analysis used different methods for hormonal assays. All measurements were conducted based on three methods including chemi/electrochemiluminescence, radioimmunoassay or enzyme, and variations in assays that can influence androgen levels. As data were grouped by assay method, the between-study heterogeneity in the subgroups was lower compared to the main analysis. However, adjustment for methods of assay did not significantly affect associations between BHPs and FG score. We also performed a subgroup analysis based on assay method to investigate the association between androgens and FG score. The findings of subgroup analysis confirmed the results, that is, testosterone was not associated with FG score.
After adjustment for quality assessment, our results did not change; the associations of FG score with A4 and DHEAS remained, indicating that this confounder had no significant effect on results. The association between A4 and FG score did not remain after adjusting for diagnostic criteria for PCOS and study design. The strengths of this meta-analysis include adjusting for potential confounders and performing subgroup analysis based on assay methods and diagnostic criteria for PCOS. The study of course has its limitations that should be considered when interpreting the findings.
The majority of studies did not report the ethnicity of patients; however, we divided countries into ethnicity groups (Western, Middle
East, Eastern and African) and adjusted for ethnicity as a confounder.
Most studies in this meta-analysis recruited participants from settings such as hospitals and clinics, which may represent a population with more severe manifestations of PCOS. In this study, we could not investigate the associations of FG score with BHPs, considering all confounders simultaneously because of the limited number of included studies.
Significant heterogeneity was found in mean FG scores between studies included in the meta-analysis, which may have resulted from clinical heterogeneity related to variability in PCOS diagnosis, race, ethnicity and/or interpreting hirsutism. Additionally, FG score is a visual and subjective scale; inter-observer variation cannot be completely eliminated. We also observed significant heterogeneity in mean BHPs between studies, which was predictable because of variability in age, BMI, SHBG concentration and assay methods. 9 Moreover, we used random effect analysis to deal with the problem. To minimize selection bias, we selected studies based on the eligibility criteria that had been set just before the study. We also performed a hand search on the references lists of all selected studies to prevent missing studies.
In conclusion, the current study demonstrated positive associations of some BHPs such as A4 and DHEAS with FG score. In most analyses, DHEAS was associated with FG score. These relationships were not causal; thus, our findings confirmed a relationship between clinical and biochemical HA. As DHEAS and A4 levels were strongly associated with hirsutism, these markers should be considered valuable to assess HA in patients with PCOS. The data suggest that peripheral androgen metabolism is one of the major determinants of hirsutism in PCOS patients.
